Section Arrow
LIMN.NASDAQ
- Liminatus Pharma Inc
(Financial Status)
Quotes are at least 15-min delayed:2026/05/26 07:01 EDT
Pre Market
Last
 0.1615
-0.0079 (-4.66%)
Bid
0.1615
Ask
0.162
High 0.1708 
Low 0.155 
Volume 656.44K 
Regular Hours (Closed)
Last
 0.1694
-0.0766 (-31.14%)
Day High 
0.182 
Prev. Close
0.246 
1-M High
0.3583 
Volume 
26.45M 
Bid
0.1615
Ask
0.162
Day Low
0.132 
Open
0.1812 
1-M Low
0.1763 
Market Cap 
11.04M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.2 
20-SMA 0.2 
50-SMA 0.2 
52-W High 33.66 
52-W Low 0.1592 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.25/--
Enterprise Value
11.04M
Balance Sheet
Book Value Per Share
-0.00
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GOVXGeoVax Labs Inc.3.64+0.89+32.36%-- 
Pre Market 3.6804 +0.0404 +1.11%
MTVAMetaVia Inc.3.85+0.98+34.15%-- 
Pre Market 3.4705 -0.3795 -9.86%
AKTXAkari Therapeutics Plc18.27+13.13+255.45%-- 
Pre Market 14.17 -4.1 -22.44%
LIMNLiminatus Pharma Inc0.1694-0.0766-31.14%-- 
Pre Market 0.1615 -0.0079 -4.66%
IOVAIovance Biotherapeutics4.11+0.41+11.08%-- 
Pre Market 4.0352 -0.0748 -1.82%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.